EANS-Adhoc: Intercell Executes Multi-Year Contract for Supply of IXIARO® to the United States Military

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Company Information

08.05.2009

» Exclusive, multi-year contract executed by Intercell and
U.S. Department of Defense for purchase of IXIARO®

» First sales of IXIARO under this military contract expected soon

Vienna (Austria), May 8, 2009 - Intercell AG (VSE: ICLL) announced
today that the Company has successfully entered into a multi-year
contract with the Defense Logistics Agency (DLA), Defense Supply
Center of the U.S. Department of Defense to supply IXIARO, a vaccine
against Japanese Encephalitis (JE). The first sales of IXIARO under
this contract are expected in the near future. This supply contract
was negotiated in response to a Request for Proposals (RFP) issued by
the DLA in August 2008. The parties were able to move forward to
finalize the contract after IXIARO was approved by the Food and Drug
Administration on March 30.

The major terms of this contract are as follows:
» Exclusive contract for Intercell to supply DLA with all their
requirements for JE vaccine
» Five-year contract, with annual options for price modifications

"With a mortality rate that can exceed 30 percent, Japanese
Encephalitis is a clear danger to the thousands of military personnel
- and their families - that are stationed in areas where the disease
is endemic. IXIARO will provide a new level of protection for this
group of people at risk," stated Gerd Zettlmeissl, Chief Executive
Officer of Intercell. "Intercell is very pleased that the Department
of Defense has acknowledged the value of IXIARO by entering into a
long-term supply agreement."

IXIARO was developed by Intercell under an agreement with the Walter
Reed Army Institute of Research (WRAIR). JE is a very serious and
growing public health threat in Asia. The U.S. military plans to use
IXIARO to protect its troops, families and contract workers who are
deployed to affected countries. Intercell will directly distribute
and market IXIARO to the U.S. military. Novartis Vaccines USA will
market and distribute the vaccine to the private market in the U.S.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market